Syn2bio (WAR:S2B) Marketable Securities: zł0.00 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:S2B Syn2bio SA WAR:S2B
9 GF Score
Price zł64.00
! 1 Warning Sign
View Full Analysis

What is Syn2bio Marketable Securities?

Syn2bio WAR:S2B -0.44% 9 Marketable Securities is zł0.00 Mil as of Sep. 2025. GuruFocus rates WAR:S2B with a GF Score™ of 9/100. The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Syn2bio's Marketable Securities for the quarter that ended in Sep. 2025 was zł0.00 Mil.

Syn2bio  (WAR:S2B) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Syn2bio Marketable Securities Related Terms

Syn2bio Marketable Securities Historical Data

* Premium members only.

The historical data trend for Syn2bio's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syn2bio Marketable Securities Chart

Syn2bio Annual Data
Trend Sep23 Sep24 Sep25
Marketable Securities
0.00 0.00 0.00

Syn2bio Semi-Annual Data
Sep23 Sep24 Sep25
Marketable Securities 0.00 0.00 0.00
WAR:S2B
9GF Score
Syn2bio SA WAR:S2B
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syn2bio Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of zł0.00 Mil mean?
Syn2bio (WAR:S2B) has a Marketable Securities of zł0.00 Mil as of Sep. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Syn2bio and its competitors.
Is Syn2bio's Marketable Securities too high?
Syn2bio's current Marketable Securities is zł0.00 Mil. Overall, Syn2bio has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Syn2bio's Marketable Securities compare to VRTX and REGN?
Syn2bio's Marketable Securities of zł0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Syn2bio and its competitors. Syn2bio's current Marketable Securities is zł0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn2bio stock overvalued right now?
Syn2bio (WAR:S2B) has a current Marketable Securities of zł0.00 Mil. The current Marketable Securities is zł0.00 Mil. Syn2bio's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Syn2bio (WAR:S2B), the current Marketable Securities is zł0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syn2bio Business Description

Address ul. Jozefa Piusa Dziekonskiego 3, Warszawa, POL, 00-728
Syn2bio SA is a Polish biotech company that develops radiopharmaceuticals. It specializes in developing a cardiac biomarker for diagnosing heart conditions like coronary artery disease through myocardial perfusion imaging. The company's flagship product is the SYN2 cardiotracer. It is applied in the detection of perfusion disorders, evaluation of patients after myocardial infarction or with ischemic heart disease, and assessment of atherosclerotic changes in coronary arteries.
9GF Score

Get the complete analysis for WAR:S2B

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł64.00
Price